enow.com Web Search

  1. Ads

    related to: polycythemia vera and surgery risks and causes treatment

Search results

  1. Results from the WOW.Com Content Network
  2. Polycythemia vera - Wikipedia

    en.wikipedia.org/wiki/Polycythemia_vera

    In oncology, polycythemia vera (PV) is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells. [1] The majority of cases [ 2 ] are caused by mutations in the JAK2 gene, most commonly resulting in a single amino acid change in its protein product from valine to phenylalanine at position 617.

  3. Polycythemia - Wikipedia

    en.wikipedia.org/wiki/Polycythemia

    Mild polycythemia on its own is often asymptomatic. Treatment for polycythemia varies, and typically involves treating its underlying cause. [6] Treatment of primary polycythemia (see polycythemia vera) could involve phlebotomy, antiplatelet therapy to reduce risk of blood clots, and additional cytoreductive therapy to reduce the number of red ...

  4. Myomatous erythrocytosis syndrome - Wikipedia

    en.wikipedia.org/wiki/Myomatous_erythrocytosis...

    Hematological values such as hemoglobin, hematocrit, and red blood cell counts are elevated in patients with myomatous erythrocytosis syndrome. [3]The diagnostic criteria for myomatous erythrocytosis syndrome includes polycythemia, uterine myoma, and return of hemoglobin levels to normal following fibroid excision surgery.

  5. Primary myelofibrosis - Wikipedia

    en.wikipedia.org/wiki/Primary_myelofibrosis

    However, splenectomy in the presence of massive splenomegaly is a high-risk procedure, with a mortality risk as high as 3% in some studies. [23] In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK ...

  6. Ropeginterferon alfa-2b - Wikipedia

    en.wikipedia.org/wiki/Ropeginterferon_alfa-2b

    [3] [6] Ropeginterferon alfa-2b is the first medication approved by the US Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. [3] The FDA considers it to be a first-in-class medication. [7]

  7. Thrombocythemia - Wikipedia

    en.wikipedia.org/wiki/Thrombocythemia

    High platelet counts can occur in patients with polycythemia vera (high red blood cell counts), and is an additional risk factor for complications. [citation needed] A very small number of people report symptoms of erythromelalgia, a burning sensation and redness of the extremities that resolves with cooling, or aspirin or both. [3]

  8. Essential thrombocythemia - Wikipedia

    en.wikipedia.org/wiki/Essential_thrombocythemia

    [15] [16] [17] Patients are usually designated as having a low or high risk of bleeding or developing blood clots based on their age, medical history, blood counts and their lifestyles. Low risk individuals are usually treated with aspirin , whereas those at high risk are treated with hydroxycarbamide , interferon-α or anagrelide ).

  9. Basophilia - Wikipedia

    en.wikipedia.org/wiki/Basophilia

    Causes: Chronic myeloid leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, acute myeloid leukemia, allergic reactions or chronic inflammation related to infections, inflammatory bowel disease, and autoimmune disease. Diagnostic method: Complete blood count and blood smear.

  1. Ads

    related to: polycythemia vera and surgery risks and causes treatment